Prelude Capital Management’s TherapeuticsMD TXMD Stock Holding History

Prelude Capital Management’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-28	Closed	-$3K	–	2049
2019 Q4	$3K	Sell	28 -4	-13%	-$575	﹤0.01%	1819
2019 Q3	$6K	Hold	32	–	–	﹤0.01%	1551
2019 Q2	$4K	Buy	+32	New	+$5.74K	﹤0.01%	1544
2019 Q1	–	Sell	-4	Closed	-$1K	–	2190
2018 Q4	$1K	Buy	+4	New	+$976	﹤0.01%	1719
2016 Q1	–	Sell	-54	Closed	-$28K	–	1530
2015 Q4	$28K	Buy	+54	New	+$19.9K	﹤0.01%	1159
2014 Q1	–	Sell	-1,400	Closed	-$365K	–	2110
2013 Q4	$365K	Buy	+1,400	New	+$307K	0.06%	453

Other funds holding TXMD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CWG

C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Prelude Capital Management's TXMD Position: Q1 2020 in Review

Prelude Capital Management sold out of TherapeuticsMD (TXMD) in Q1 2020, closing a stake of 28 shares — an estimated $3K sold.

Prelude Capital Management first reported a position in TXMD in Q4 2013 and held it in 6 quarters. The position peaked at $365K in Q4 2013. 143 funds tracked by Wall St. Rank hold TXMD as of Q1 2020.

Prelude Capital Management reported no remaining TherapeuticsMD position as of Q1 2020 after selling out during the quarter.
Prelude Capital Management sold 28 TherapeuticsMD shares in Q1 2020, an estimated $3K.
Prelude Capital Management first reported a position in TherapeuticsMD in Q4 2013 and held it in 6 quarters.
Prelude Capital Management's TherapeuticsMD position peaked at $365K in Q4 2013.
143 funds tracked by Wall St. Rank held TherapeuticsMD as of Q1 2020.

Based on Prelude Capital Management's 13F filing for Q1 2020, filed 15 May 2020.